Co-publishing and Innovation. Bioscience Defies a ‘One-Size-Fits-All’ Definition

To what extent is innovation comparable across industries? The Schumpeterian literature suggests it is — thus it can be radical, incremental or based on recombination in product, process or organization to name two sets of three of the generic types commonly analyzed in innovation studies conducted from a neo-Schumpeterian perspective. But, as Henderson et al.(1999) show, Schumpeterian thinking was driven by an engineering metaphor in which ‘gales of creative destruction’ removed swathes of industry, and certainly skills, as firms unable to compete with new technologies became bankrupt. This occurred classically in textiles with the handloom weavers and the onset of factory organization and power-loom technology, it happened when sailing ships gave way to steam, and it is happening today as biotechnology replaces synthetic, fine chemistry in pharmaceuticals. Or is it? That is the question that prompts this chapter.

[1]  Helen Lawton-Smith The biotechnology industry in Oxfordshire: enterprise and innovation , 2004 .

[2]  J. Kay The Truth About Markets , 2003 .

[3]  Phil Cooke,et al.  Clusters and Regional Specialisation , 2001 .

[4]  Dan Kaufmann,et al.  The Role of Location and Regional Networks for Biotechnology Firms in Israel , 2003 .

[5]  Fritjof Capra,et al.  The Hidden Connections , 2002 .

[6]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[7]  Eike W. Schamp,et al.  Dimensions of proximity in knowledge-based networks: The cases of investment banking and automobile design , 2004 .

[8]  David C. Mowery,et al.  Sources of Industrial Leadership , 1999 .

[9]  Paul Krugman,et al.  Development, Geography, and Economic Theory , 1995 .

[10]  Ann Bruce,et al.  Assessing end-use relevance of public sector research organisations , 2004 .

[11]  Rebecca Henderson,et al.  Sources of Industrial Leadership: The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change , 1999 .

[12]  J. Bart Carrin,et al.  SCIENCE-TECHNOLOGY-INDUSTRY NETWORK "THE COMPETITIVENESS OF SWISS BIOTECHNOLOGY": A CASE STUDY OF INNOVATION , 2004 .

[13]  Watson Mr.,et al.  Signs of Life , 1997 .

[14]  Rikard Stankiewicz,et al.  The Cognitive Dynamics of Biotechnology and the Evolution of Its Technological Systems , 2002 .

[15]  Meric S. Gertler,et al.  The Oxford Handbook of Economic Geography , 2003 .

[16]  Steven Casper,et al.  The Road to Sustainability in the UK and German Biotechnology Industries , 2000 .

[17]  H. Smith,et al.  The biotechnology industry in Oxfordshire: enterprise and innovation , 2004 .

[18]  D. Teece,et al.  The Dynamic Capabilities of Firms: an Introduction , 1994 .

[19]  Walter W. Powell,et al.  Knowledge Networks as Channels and Conduits: The Effects of Spillovers in the Boston Biotechnology Community , 2004, Organ. Sci..

[20]  Peter Maskell,et al.  Localized Learning and Industrial Competitiveness , 1995 .

[21]  Kathleen M. Eisenhardt,et al.  How Breakthroughs Happen: The Surprising Truth About How Companies Innovate , 2003 .

[22]  Paul Nightingale,et al.  Economies of Scale in Experimentation: Knowledge and Technology in Pharmaceutical R&D , 2000 .

[23]  Frances Cairncross,et al.  The death of distance , 1997 .

[24]  Christian Zeller North Atlantic Innovative Relations of Swiss Pharmaceuticals and the Proximities with Regional Biotech Arenas , 2004 .

[25]  How do firms innovate , 2004 .